Given that the research team seems to be a clinical based team in the United Kingdom, it's possible that some may have been drafted into the COVID-19 response. This may explain the delay of the results which was initially set for late Q1/early Q2.
If this Phase 2 doesn't deliver, I expect the SP to tank.
IXC Price at posting:
$1.01 Sentiment: Hold Disclosure: Held
